You are here

Article Text

Article menu
Download PDFPDF
Letter
Unsuccessful rescue therapy with adefovir dipivoxil for lamivudine resistant HBV in a patient with liver failure
  1. D Thabut1,
  2. V Ratziu1,
  3. B Bernard-Chabert1,
  4. T Poynard1,
  5. Y Benhamou1,
  6. V Thibault2
  1. 1Service d’Hépato-Gastroentérologie, Groupe Hospitalier Pitié-Salpêtriére, Paris, France
  2. 2Service de Virologie, Groupe Hospitalier Pitié-Salpêtriére, Paris, France
  1. Correspondance to:
    D Thabut, Service d’Hépato-Gastroentérologie, 47-83 Bld de l’Hôpital, 75013 Paris, France;
    dthabut{at}libertysurf.fr

https://doi.org/10.1136/gut.52.4.614-a

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Adefovir dipivoxil is a new nucleoside analogue which is active against lamivudine resistant hepatitis B virus (HBV). A 48 week course of adefovir in human immunodeficiency virus type 1 infected patients with lamivudine resistant HBV induces a rapid and major decrease in serum HBV DNA levels with improvement in liver inflammation.1 Although reassuring, this efficacy of adefovir may be influenced by the timing of its initiation after the emergence of lamivudine resistant HBV. We report here the case of a cirrhotic patient treated with lamivudine for four years who died of liver failure due to the emergence of lamivudine resistant HBV, despite the introduction of …

    View Full Text